Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
78.47 USD | -2.45% |
|
+1.02% | +12.78% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an enterprise value anticipated at 3.36 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.78% | 1.32TCr | - | ||
+61.53% | 85TCr | C+ | ||
+34.31% | 63TCr | B | ||
-3.66% | 36TCr | C+ | ||
+15.06% | 32TCr | B- | ||
+9.18% | 30TCr | C+ | ||
+11.66% | 23TCr | A+ | ||
+15.48% | 23TCr | B- | ||
+15.67% | 18TCr | C+ | ||
+2.47% | 17TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DRREDDY Stock
- RDY Stock
- Ratings Dr. Reddy's Laboratories Limited